Mesothelioma Therapy Immunotherapy and Targeted Therapy 3

Question 1

Which immune checkpoint combination showed a statistically significant overall survival benefit in CheckMate 743 for mesothelioma?

Accepted Answer

Nivolumab + ipilimumab vs. chemotherapy

Answer

Nivolumab + chemotherapy

Answer

Pembrolizumab + ipilimumab

Answer

Atezolizumab + nivolumab

Question 2

Tumor Treating Fields (TTFields) therapy is approved in the US for mesothelioma in combination with which treatment?

Accepted Answer

Pemetrexed + platinum chemotherapy

Answer

Surgery alone

Answer

Immunotherapy only

Answer

Radiation therapy alone

Question 3

What is the mechanism of Tumor Treating Fields (TTFields) therapy?

Accepted Answer

Creating alternating electric fields that disrupt cancer cell division

Answer

Delivering localized radiation

Answer

Delivering heat to destroy tumors

Answer

Stimulating immune checkpoint activation

Question 4

Which serum biomarker may be used to monitor response to immunotherapy in mesothelioma?

Accepted Answer

Soluble mesothelin-related peptides (SMRP)

Answer

PSA

Answer

AFP

Answer

CA 19-9

Question 5

Which genetic pathway alteration is under investigation as a target in sarcomatoid mesothelioma?

Accepted Answer

SWI/SNF chromatin remodeling complex (SMARCA4/ARID1A)

Answer

HER2 amplification

Answer

CDK4/6 pathway

Answer

VEGFR pathway

Question 6

What is the primary reason immunotherapy shows greater benefit in non-epithelioid mesothelioma compared to chemotherapy?

Accepted Answer

Non-epithelioid cells are resistant to chemotherapy, making immunotherapy relatively more effective

Answer

Non-epithelioid cells overexpress PD-L1

Answer

Non-epithelioid cells are chemotherapy-sensitive

Answer

Immunotherapy works by a different mechanism in each cell type